Skip to content
Telehealth Graded
Buyer guide

Compounded tirzepatide in 2026: legal status and cost

Yes, compounded tirzepatide is still legal in 2026, but only within limits. The national shortage that allowed pharmacies to copy Zepbound and Mounjaro is over, confirmed by the FDA in December 2024, so a state-licensed pharmacy may still fill a prescription for it, yet may not regularly make copies of the approved drug unless a prescriber documents a change that makes a significant difference for that patient[1][3]. On price, half of the 210 sellers we track list compounded tirzepatide at $215 a month or less, against $299 for the lowest Zepbound dose on LillyDirect.

J. Merrick · Published · 10 sources · 7 min read

Educational content, not medical advice. Talk to a licensed clinician before starting any treatment.

What this comes down to

  • The FDA declared the tirzepatide shortage resolved in October 2024, confirmed it in December 2024, and its grace periods for compounders ended in early 2025. Tirzepatide is not on the FDA's shortage list today.
  • A 503A pharmacy may compound tirzepatide for a named patient, but not copies of the approved drug regularly or in inordinate amounts. A change the prescriber says makes a significant difference for that patient is what takes a vial out of the copy rule.
  • Each seller's lowest monthly figure for compounded tirzepatide runs from $69 to $679.95; half list $215 or less. The lowest Zepbound listing on LillyDirect is $299.
  • In March 2026 the FDA sent 30 warning letters to telehealth companies over compounded GLP-1 claims. A seller that calls its vial generic, FDA-approved or the same as Zepbound is making a claim the FDA has called false or misleading.
Compounded tirzepatide per month, against Zepbound on LillyDirect
  • Lowest seller floor$69
  • Half of sellers at or below$215
  • Highest seller floor$679.95
  • Zepbound KwikPen 2.5 mg, LillyDirect$299

Each seller's lowest listed monthly figure for injectable compounded tirzepatide, from its public website.

Tirzepatide injection was in shortage from 2022 until October 2, 2024, when the FDA determined the shortage resolved. After a court remand it re-evaluated and reached the same decision on December 19, 2024, and gave compounders a grace period: until February 18, 2025 for state-licensed 503A pharmacies and March 19, 2025 for 503B outsourcing facilities, or until a pending court ruling, whichever came later[1]. Tirzepatide does not appear on the FDA's current shortage list[2].

What remains is the ordinary law. A 503A pharmacy may not compound, regularly or in inordinate amounts, drugs that are essentially copies of a commercially available drug, and a vial is not a copy when it carries a change, made for an identified patient, that produces a significant difference for that patient as determined by the prescriber[3]. In practice that is why so many compounded tirzepatide offers come with a different dose schedule or an added ingredient. Tirzepatide itself is an allowed 503A ingredient because it is a component of an approved drug[4].

Outsourcing facilities face a tighter rule. On April 30, 2026 the FDA proposed not to put tirzepatide, semaglutide or liraglutide on the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk[5]. The comment period was extended to July 30, 2026[6], and the FDA has said it will consider comments before a final determination. How to check a compounding pharmacy explains the 503A and 503B difference and where each is listed.

Compounded is not generic, and it is not Zepbound

Zepbound's approval rests on trials such as SURMOUNT-1, where 72 weeks of the 15 mg dose produced an average weight change of -20.9%, against -3.1% on placebo[10]. Those results belong to the approved product. Compounded drugs are not FDA-approved, and the agency does not review their safety, effectiveness or quality before they are sold[7].

How much does compounded tirzepatide cost per month?

We list 210 sellers that publish a price for injectable compounded tirzepatide on their own websites, read between September 2026 and October 2026. Taking the lowest monthly figure each one publishes, often the per-month rate on a three-, six- or twelve-month plan, the range runs from $69 at Collective to $679.95 at TeleWellnessMD, and half of the sellers list $215 or less. Most raise the price as the dose climbs, so the month-four bill is usually higher than the first; what a dose increase does to the bill covers how that adds up.

WhatA month
Lowest seller floor$69
Half of sellers at or below$215
Highest seller floor$679.95
Zepbound KwikPen 2.5 mg on LillyDirect$299
Zepbound 10 mg, 12.5 mg and 15 mg on LillyDirect$699

Lowest listed monthly figure per seller, injectable compounded tirzepatide, read between September 2026 and October 2026. Zepbound prices as listed on LillyDirect.

Every seller, with its month-one and month-to-month price side by side, is on the compounded tirzepatide price board.

Is compounded tirzepatide cheaper than Zepbound?

Usually, at the starting dose, though by less than the headline suggests. LillyDirect lists the Zepbound KwikPen 2.5 mg at $299 a month and the Zepbound 10 mg, 12.5 mg and 15 mg at up to $699, read in September 2026 for our LillyDirect review. Half of the compounded sellers list $215 or less, but that is often a prepaid-plan rate, and many add a membership fee on top. Brand versus compounded, priced side by side runs the comparison dose by dose.

How do you check the pharmacy behind compounded tirzepatide?

  1. Ask the seller to name the pharmacy and the state that licenses it. The FDA has warned telehealth companies against branding that implies they are the compounder[8].
  2. Look the pharmacy up: the FDA's outsourcing-facility register for a 503B, or the state board of pharmacy for a 503A. How to check a compounding pharmacy shows both lookups.
  3. Check the vial label against that name. The FDA has found compounded tirzepatide whose label named a pharmacy that does not exist, or a licensed pharmacy that did not make it[9].
  4. Ask what the beyond-use date is. The FDA recommends discarding a multi-dose vial 28 days after first use, whatever the label says, and not using any shipment that arrives warm[9]. Storage and beyond-use dating goes further.

What red flags has the FDA named?

  • Claims that a compounded drug is generic, FDA-approved, clinically proven to match the approved drug, or made by an FDA-approved or FDA-licensed pharmacy. The FDA does not approve or license any pharmacy[8].
  • Sameness claims and seller-branded vials were the main violations in the 30 warning letters the FDA sent on March 3, 2026[7].
  • Products sold for research purposes or not for human consumption. The FDA urges consumers not to buy them[9]. The same label is common on peptide sites, which are peptides legal? covers.
  • Doses beyond the approved label or a faster climb than the label's schedule. The FDA has adverse event reports tied to both, and as of May 31, 2026 had received more than 730 reports involving compounded tirzepatide[9].

Which of the sellers we work with list compounded tirzepatide?

Some providers pay us a commission when you sign up through our links, at no extra cost to you. Providers we work with may appear first. Each review below covers the pharmacy, the month-two price and the cancellation terms. Every seller we price is on the price board or all reviews.

Questions people actually ask

Is compounded tirzepatide still legal in 2026?

Yes, within limits. A state-licensed pharmacy can fill a prescription for it, but since the shortage ended it may not regularly make copies of Zepbound or Mounjaro unless the prescriber documents a change that makes a significant difference for that patient.

How much does compounded tirzepatide cost?

Each seller's lowest listed monthly figure runs from $69 to $679.95 across the 210 sellers we track, and half list $215 or less. Prices usually rise with the dose.

Is compounded tirzepatide the same as Zepbound?

No. It has the same active ingredient, but it is not FDA-approved, and the FDA does not review its safety, effectiveness or quality before sale. The FDA has called claims of sameness with the approved drug false or misleading.

Why did the FDA send warning letters to telehealth companies?

On March 3, 2026 the FDA announced 30 warning letters to telehealth companies over compounded GLP-1 marketing. The main problems were claims implying the products are the same as approved drugs, and branding that implied the telehealth company was the compounder.

How do I know my compounded tirzepatide pharmacy is real?

Ask the seller to name the pharmacy, look it up on the FDA outsourcing-facility register or your state board of pharmacy, and check that the vial label names the same pharmacy. The FDA has found labels naming pharmacies that do not exist.

Sources

Every source below was read for this article, with the claim it supports written beside it.

  1. 1.
    FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. U.S. Food and Drug Administration, 2026. Source · Document dated April 2026
    Tirzepatide injection shortage resolved October 2, 2024 and again on re-evaluation December 19, 2024; grace periods to February 18, 2025 (503A) and March 19, 2025 (503B), or the court's preliminary-injunction ruling if later. Section 503A restricts compounding essentially copies of a commercially available drug, permitted only if not regularly or in inordinate amounts.
  2. 2.
    FDA Drug Shortages: current and resolved shortages and discontinuations. U.S. Food and Drug Administration, 2026. Source
    On October 5, 2026 tirzepatide did not appear on the FDA's drug shortage list, which listed liraglutide injection as currently in shortage.
  3. 3.
    21 U.S. Code § 353a — Pharmacy compounding. Legal Information Institute, Cornell Law School (United States Code), 2026. Source
    Section 353a(b)(1)(D) bars compounding regularly or in inordinate amounts drugs that are essentially copies of a commercially available drug; (b)(2) excludes a change made for an identified patient that produces a significant difference for that patient, as determined by the prescribing practitioner.
  4. 4.
    Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. U.S. Food and Drug Administration, 2026. Source · Document dated May 2026
    A 503A compounder may use a bulk substance that is a component of an FDA-approved drug product, has a USP or NF monograph, or is on the 503A bulks list.
  5. 5.
    FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. U.S. Food and Drug Administration, 2026. Source · Document dated April 2026
    On April 30, 2026 the FDA proposed not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list, finding no clinical need, and said it will consider comments before a final determination.
  6. 6.
    List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period. Federal Register, 2026. Source · Document dated June 2026
    The comment period on the 503B proposal was extended; comments were due by July 30, 2026.
  7. 7.
    FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. U.S. Food and Drug Administration, 2026. Source · Document dated March 2026
    On March 3, 2026 the FDA announced 30 warning letters to telehealth companies over false or misleading compounded GLP-1 claims, chiefly claims implying sameness with approved products and seller-branded products implying the telehealth firm is the compounder; compounded drugs are not FDA-approved and not reviewed for safety, effectiveness or quality before marketing.
  8. 8.
    FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs. U.S. Food and Drug Administration, 2026. Source · Document dated June 2026
    The FDA reminds telehealth companies not to imply they are the compounder, call a compounded drug generic or the same as an approved drug, claim FDA approval or clinical proof of equal results, or claim sourcing from an FDA-approved or FDA-licensed pharmacy; the FDA does not approve or license any facility.
  9. 9.
    FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration, 2026. Source · Document dated October 2026
    Fraudulent compounded tirzepatide labels naming nonexistent pharmacies or pharmacies that did not compound the product; discard multi-dose vials 28 days after first use; do not use shipments that arrive warm; adverse events tied to doses beyond the label; more than 730 adverse event reports for compounded tirzepatide as of May 31, 2026; research-labeled products.
  10. 10.
    Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022. PMID 35658024 · doi:10.1056/NEJMoa2206038
    In 2,539 adults over 72 weeks, mean weight change was -15.0%, -19.5% and -20.9% on 5, 10 and 15 mg of tirzepatide against -3.1% on placebo.

Key figures

Sellers with a listed price
210
Half list at or below
$215 a month
Range of seller floors
$69 to $679.95
Warning letters, March 2026
30